Last reviewed · How we verify
OMP-18R5
At a glance
| Generic name | OMP-18R5 |
|---|---|
| Sponsor | OncoMed Pharmaceuticals, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors (PHASE1)
- A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC (PHASE1)
- A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer (PHASE1)
- A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OMP-18R5 CI brief — competitive landscape report
- OMP-18R5 updates RSS · CI watch RSS
- OncoMed Pharmaceuticals, Inc. portfolio CI